Curevac and gsk's bivalent second-generation mrna vaccine candidate shown to be highly effective against sars-cov-2 variants in preclinical study

- vaccine candidate combining beta- and delta-specific mrnas shows strong protection and immune responses during preclinical challenge study - demonstrated neutralizing capacity against the omicron variant in vaccinated animals - technology adaptation for bivalent approach for covid-19 vaccines potentially allows for broader protection against emerging variants tÜbingen, germany and boston, ma / accesswire / april 21, 2022 / curevac n.v. (nasdaq:cvac), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mrna"), today announced preclinical data demonstrating immune responses and protective efficacy of a bivalent second-generation covid-19 vaccine candidate jointly developed with gsk, combining two mrnas encoding for the beta and the delta variant.
CVAC Ratings Summary
CVAC Quant Ranking